COVID-19 vaccine being developed by Oxford University and AstraZeneca, a move it hopes will speed any eventual approval.In a statement Thursday, the EU regulator said instead of waiting for all of the required vaccine data to be submitted before beginning its assessment, the EMA has begun analyzing the preliminary information from scientists on the Oxford vaccine.That data suggests the vaccine “triggers the production of antibodies and T-Cells," referring to immune system cells that target the virus.
The agency said it was waiting for data from ongoing late-stage tests of the vaccine involving thousands of people, which it hopes will be shared in the coming weeks and months.“The rolling review will continue until enough evidence is.